Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diana Otero Svaldi

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Neuroimage. Clinical|November 7, 2024
Tau-network mapping of domain-specific cognitive impairment in Alzheimer's diseaseYing Luan, Anna Rubinski, Davina Biel, et al.
Alzheimer'S & Dementia (New York, N. Y.)|July 5, 2022
Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementiaDiana Otero Svaldi, Ixavier A Higgins, Karen C Holdridge, et al.
Neuroimage|July 24, 2020
GEFF: Graph embedding for functional fingerprintingKausar Abbas, Enrico Amico, Diana Otero Svaldi, et al.
Frontiers in Aging Neuroscience|September 7, 2021
Predicting the Emergence of Major Neurocognitive Disorder Within Three Months After a StrokeEva Birgitte Aamodt, Till Schellhorn, Edwin Stage, et al.
JAMA Neurology|November 6, 2023
ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid LevelsAnna Steward, Davina Biel, Anna Dewenter, et al.
Annals of Neurology|October 14, 2023
Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer DiseaseLukai Zheng, Anna Rubinski, Jannis Denecke, et al.
Alzheimer'S Research & Therapy|November 8, 2022
Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's diseaseDavina Biel, Ying Luan, Matthias Brendel, et al.
The Journal of Prevention of Alzheimer'S Disease|July 6, 2025
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, et al.
Alzheimer'S & Dementia (New York, N. Y.)|February 22, 2021
Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's diseaseJennifer A Zimmer, Sergey Shcherbinin, Michael D Devous, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 9, 2025
Multimodal spatial gradients to explain regional susceptibility to fibrillar tau in Alzheimer's diseaseYing Luan, Lukai Zheng, Jannis Denecke, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Neuroimage. Clinical|November 7, 2024
Tau-network mapping of domain-specific cognitive impairment in Alzheimer's diseaseYing Luan, Anna Rubinski, Davina Biel, et al.
Alzheimer'S & Dementia (New York, N. Y.)|July 5, 2022
Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementiaDiana Otero Svaldi, Ixavier A Higgins, Karen C Holdridge, et al.
Neuroimage|July 24, 2020
GEFF: Graph embedding for functional fingerprintingKausar Abbas, Enrico Amico, Diana Otero Svaldi, et al.
Frontiers in Aging Neuroscience|September 7, 2021
Predicting the Emergence of Major Neurocognitive Disorder Within Three Months After a StrokeEva Birgitte Aamodt, Till Schellhorn, Edwin Stage, et al.
JAMA Neurology|November 6, 2023
ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid LevelsAnna Steward, Davina Biel, Anna Dewenter, et al.
Annals of Neurology|October 14, 2023
Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer DiseaseLukai Zheng, Anna Rubinski, Jannis Denecke, et al.
Alzheimer'S Research & Therapy|November 8, 2022
Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's diseaseDavina Biel, Ying Luan, Matthias Brendel, et al.
The Journal of Prevention of Alzheimer'S Disease|July 6, 2025
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, et al.
Alzheimer'S & Dementia (New York, N. Y.)|February 22, 2021
Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's diseaseJennifer A Zimmer, Sergey Shcherbinin, Michael D Devous, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 9, 2025
Multimodal spatial gradients to explain regional susceptibility to fibrillar tau in Alzheimer's diseaseYing Luan, Lukai Zheng, Jannis Denecke, et al.
Pageof 2